Pancreatic Cancer Research

ResearcherUniversity of MichiganActive in the last 2 years

Megan T. Hoffman

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0003-0907-9977; OpenAlex author ID A5035111732. Sources: OpenAlex.

Their work

Papers
11 (first author 4, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
83
Papers, trials and grants by year

2016: 1 paper · 2017: 1 paper · 2018: none · 2019: none · 2020: none · 2021: 2 papers · 2022: 1 paper · 2023: 2 papers · 2024: 1 paper · 2025: 1 paper · 2026: 2 papers

Papers 11

  1. CD4 T cells convert transient responses to KRAS inhibition to durable remissions in pancreatic cancer. First author DOI 10.1016/j.cell.2026.08.045↗
  2. Growth factor supportive care for chemotherapy-induced neutropenia suppresses antitumour immunity in checkpoint blockade-responsive pancreatic cancer. Co-author DOI 10.1093/immadv/ltag013↗
  3. Tuft cells transdifferentiate to neural-like progenitor cells in the progression of pancreatic cancer. First author DOI 10.1016/j.devcel.2024.12.003↗
  4. Mechanisms of Resistance to Oncogenic KRAS Inhibition in Pancreatic Cancer. First author DOI 10.1158/2159-8290.cd-24-0177↗
  5. Ornithine aminotransferase supports polyamine synthesis in pancreatic cancer. Co-author DOI 10.1038/s41586-023-05891-2↗
  6. Transforming Growth Factor-β Blockade in Pancreatic Cancer Enhances Sensitivity to Combination Chemotherapy. First author DOI 10.1053/j.gastro.2023.05.038↗
  7. Metabolic requirement for GOT2 in pancreatic cancer depends on environmental context. Co-author DOI 10.7554/elife.73245↗
  8. The Gustatory Sensory G-Protein GNAT3 Suppresses Pancreatic Cancer Progression in Mice. Co-author DOI 10.1016/j.jcmgh.2020.08.011↗
  9. Inhibition of Hedgehog Signaling Alters Fibroblast Composition in Pancreatic Cancer. Co-author DOI 10.1158/1078-0432.ccr-20-3715↗
  10. MYC regulates ductal-neuroendocrine lineage plasticity in pancreatic ductal adenocarcinoma associated with poor outcome and chemoresistance. Co-author DOI 10.1038/s41467-017-01967-6↗
  11. PDX1 dynamically regulates pancreatic ductal adenocarcinoma initiation and maintenance. Co-author DOI 10.1101/gad.291021.116↗

Closest collaborators

The 25 strongest of 83 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Stephanie K. Dougan · 4 shared papers, 2023–2026 · strength 0.83
  2. Michael Lawrence Dougan · 3 shared papers, 2023–2026 · strength 0.69
  3. Andrew J. Aguirre · 3 shared papers, 2023–2026 · strength 0.69
  4. Howard C. Crawford · 6 shared papers, 2016–2025 · strength 0.61
  5. Brendan D. Parent · 2 shared papers, 2026 · strength 0.54
  6. Nina G. Steele · 4 shared papers, 2021–2025 · strength 0.51
  7. Daniel James Salas-Escabillas · 2 shared papers, 2021–2025 · strength 0.32
  8. Simone Benitz · 2 shared papers, 2021–2025 · strength 0.32
  9. Samantha B. Kemp · 3 shared papers, 2021–2022 · strength 0.30
  10. Yaqing Zhang · 3 shared papers, 2021–2022 · strength 0.30
  11. Marina Pasca di Magliano · 3 shared papers, 2021–2022 · strength 0.30
  12. Rosalie C. Sears · 2 shared papers, 2017–2025 · strength 0.26
  13. Brittany L. Allen-Petersen · 2 shared papers, 2017–2025 · strength 0.26
  14. Christopher J. Halbrook · 3 shared papers, 2016–2022 · strength 0.24
  15. Kathleen E. DelGiorno · 1 shared paper, 2025 · strength 0.21
  16. Filip Bednar · 2 shared papers, 2021 · strength 0.20
  17. Zeribe C. Nwosu · 2 shared papers, 2021–2022 · strength 0.19
  18. Costas Andreas Lyssiotis · 2 shared papers, 2021–2022 · strength 0.19
  19. Harshabad Singh · 1 shared paper, 2026 · strength 0.19
  20. Courtney T.S. Kureshi · 1 shared paper, 2026 · strength 0.19
  21. Chong Zuo · 1 shared paper, 2026 · strength 0.19
  22. George Molina · 1 shared paper, 2026 · strength 0.19
  23. Thomas E. Clancy · 1 shared paper, 2026 · strength 0.19
  24. Qiang Li · 1 shared paper, 2026 · strength 0.19
  25. Douglas Adam Rubinson · 1 shared paper, 2026 · strength 0.19

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.